Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunitiesJessica Konen, Don L. Gibbons, Haoyi Wu|Trends in Pharmacological Sciences|2024Cited by 53
Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti–PD-1 resistance in non–small cell lung cancerJessica Konen, Don L. Gibbons, Lixia Diao et al.|Journal of Clinical Investigation|2023Cited by 24
571 Exploring anti-PD-1 resistance mechanisms for therapeutic targeting in non-small cell lung cancerHaoyi Wu, Don L. Gibbons, Jessica Konen et al.|Regular and Young Investigator Award Abstracts|2023Cited by 1
450 Increased activity of the ATX/LPA axis diminishes CD8+ T cell cytotoxicity via LPAR5 signaling, driving immune checkpoint blockade resistance in non-small cell lung cancerJessica Konen, Don L. Gibbons, B. Leticia Rodriguez et al.|Regular and Young Investigator Award Abstracts|2022Cited by 0
545 ATX/LPA upregulation via microRNA-29 loss suppresses cytotoxic T cells and promotes resistance to anti-PD-1 in non-small cell lung cancerJessica Konen, Don L. Gibbons, Stephanie Schmidt et al.|Regular and Young Investigator Award Abstracts|2023Cited by 0